Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Market Oversight topic
No spam. Unsubscribe anytime.
HPC flags possible spending impact from UMass–Marlborough proposal and votes to launch retrospective review of Beth Israel Lahey merger
Summary
HPC staff said a proposed change that would place Marlborough Hospital on UMass Memorial Medical Center’s license could raise commercial spending by about $5–6.7 million annually if rates change; the commission did not open a full cost-market impact review for that transaction but the board voted to begin a retrospective CMIR of the 2019 Beth Israel Lahey Health formation at DPH’s request.
Commission staff reported a preliminary market review that found the proposed onboarding of Marlborough Hospital onto UMass Memorial Medical Center’s license could raise commercial spending if Marlborough were paid rates comparable to the academic medical center.
In a staff presentation, the commission summarized the transaction and UMass’s rationale — improved access to specialty services, staffing stability, and integrated care coordination. Staff concluded the merger "would be likely to result in an annual spending impact of approximately 5 to 6.7 million" if rates move to AMC-level pricing, while acknowledging some payer- and patient-level savings from avoided ambulance transfers (estimated $600,000–$2 million annually) and potential access benefits. The HPC said it would continue to monitor UMass pricing going forward.
Staff also noted a related determination-of-need application to add proton therapy services at Marlborough with an estimated capital cost of $53.6 million; staff said DPH will examine clinical need in its DO review and that under new guidance similar proposals will be noticed to the HPC in the future.
Separately, the board voted to accept a Department of Public Health request to initiate the commission’s first retrospective cost and market impact review (CMIR) of the 2019 formation of Beth Israel Lahey Health. The retrospective CMIR will examine post-merger impacts on spending, market dynamics, quality and equity and will proceed under the commission’s standard process (information requests, staff and consultant analysis, preliminary report, response opportunity, final report) with an approximate 185-day timeline.
Why it matters: staff said UMass Memorial is one of the state’s largest systems and has shown some of the largest price increases in recent years. The board’s decision to pursue a retrospective CMIR of BIH follows pre-existing DO conditions and an earlier agreement imposing a limit on price growth tied to the merger; the CMIR will inform oversight by DPH and the attorney general’s office.
Next steps: staff will continue monitoring UMass market activity and, following the board vote, will initiate the retrospective CMIR process for BIH per DPH’s request.
